References
- Canellos G P. Current therapeutic strategies in Hodgkin's disease. Ann Oncol 1992; 3(Suppl 4)S67–S68
- Longo D O, Young R C, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295–1306
- Vose J M, Biermann P J, Anderson J R, et al. ChlVPP chemotherapy with involved‐field irradiation for Hodgkin's disease: favorable results with acceptable toxicity. J Clin Oncol 1991; 9: 1421–1425
- Swerdlow A J, Barber J A, Horwich A, et al. Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital. Br J Cancer 1997; 75: 116–123
- Bonadonna G, Zucchi R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine and imidazole carboxamine versus MOPP. Cancer 1975; 36: 252–259
- Santoro A, Bonadonna G, Valagussa P, et al. Long term results of combined chemotherapy‐radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5: 27–37
- Goldie J H, Coldman A J. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727–1733
- Klimo P, Connors J M. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 1985; 3: 1174–1182
- Viviani S, Bonadonna G, Santoro A, et al. Alternating versus Hybrid MOPP‐ABVD in Hodgkin's disease: The Milan experience. Ann Oncol 1991; 2: 55–62
- Taylor M E, McElwain T J, Barret A, et al. Etoposide as single agent in advanced relapsed lymphomas. A phase II study. Cancer Chemoter Pharmacol 1982; 7: 175–177
- Cavalli F. VP‐16 in the treatment of malignant lymphomas: a report from the Swiss Group for Clinical Cancer Research (SAKK). Semin Oncol 1985; 12: 33–36
- Lukes R J, Gompel L F, Hall T C, et al. Report of Nomenclature Committee. Rye Classification. Cancer Res 1966; 26: 1311–1320
- Berard C W, Hutchison R E. The problem of classifying lymphomas: An orderly prescription for progress. Ann Oncol 1997; 8(Suppl 2)S3–S9
- Carbone P P, Kaplan H S, Musshoff K, et al. Report of the committee of Hodgkin's disease staging. Ann Arbor classification. Cancer 1971; 31: 1860–1861
- Miller A B, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 65–74
- Kaplan E L, Meier P. Non‐parametric estimation from incomplete observation. J Am Slat Assoc 1958; 54: 457–481
- Peto R, Armitage P, Breslow N R, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 1977; 35: 1–39
- Zar J H. Biostatistical analysis. Prentice‐Hall, Engle‐wood, NJ 1984; 378–379
- Canellos G P, James M D, Anderson J R, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478–1484
- Fuchs R, Loeffler M, Pfreundschuh M, et al. Prognosis of high dose chemotherapy/autologous bone marrow transplantation candidates not receiving this treatment after failure of primary therapy of Hodgkin's disease. Leuk Lymph 1994; 14: 79–89
- Pfreundschuh M, Rueffer U, Lathan B, et al. Dexa‐BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: A trial of the German Hodgkin's Disease Study Group. J Clin Oncol 1994; 12: 580–586
- Hancock B W, Vaughan Hudson G, Vaughan Hudson B, et al. BNLI randomized study of MOPP against LOPP in advanced Hodgkin's disease‐long term results. Br J Cancer 1991; 63: 579–582
- Selby P, Patel P, Milan S, et al. ChlVPP combination chemotherapy for Hodgkin's disease: Long‐term results. Br J Cancer 1990; 62: 279–285
- Glick J H, Young M L, Harrington D, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure‐free and overall survival: the 8‐year results of the Intergroup Trial. J Clin Oncol 1998; 16: 9–26
- O'Reilly S E, Klimo P, Connors J M, et al. The evolving role of etoposide in the management of lymphomas and Hodgkin's disease. Cancer 1991; 67: 271–280
- Kumar L. Epipodophyllotoxins and secondary leukemia. Lancet 1993; 342: 819–820